EHA 2021 | Frontline therapy for adult Ph+ ALL: chemotherapy-free regimens and the role of MRD
Robin Foà
• 14 Jun 2021
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, gives an overview of frontline therapy options for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), talking on key developments over the past couple of decades, and commenting on future approaches. Prof. Foà highlights the role of immunotherapy, commenting on the use of blinatumomab, ponatinib and dasatinib, and the possibility of curing patients with Ph+ ALL without chemotherapy or transplantation. Prof. Foà also discusses the importance of molecular monitoring, highlighting the use of measurable residual disease (MRD) detection. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
